About this toolkit

The main contact for this toolkit is loth.shcggenquiries@nhs.scot

Content has been checked for accessibility in line with the relevant RDS standard operating procedure

The app:

• is compliant with Android and Apple accessibility standards for native mobile apps
• is supported by Android 4.4 or later and iOS 8.0 or later devices.

The website:

• is compliant with WC3A 2.0 Standards
• is optimised for use on both desktop and mobile devices in the following browsers - IE9+, Chrome, Edge and Safari

The Editorial Team monitors content on an ongoing basis and reviews content upon agreed review dates.

Key content suppliers can notify the Editorial Team of required updates to to any published/linked resources as and when needed. The Editorial Team will approve non guideline content and can do this outwith scheduled group meetings.

RDS automated alerts when review is due will be sent to the Editorial Team.

Unless otherwise indicated, copyright in this toolkit is retained by the Scottish Cancer Strategy Board. Users may download or print copies for their own use.

All icons are from Flaticon.com, accessed through the licence held Tactuum Ltd for the resources supported by the software platform it provides.

The content within this toolkit is based on current evidence and best practice, however it is intended to be applied alongside sound practitioner judgement. As such, the Scottish Cancer Strategy Board is not responsible or liable for management decision made on the basis of the information provided via this toolkit.

Use of this toolkit within education settings should always be in accordance with local policies and guidance with regard to practice and mobile device usage.

The Scottish Cancer Strategy Board is not responsible for the content of any external websites listed, nor do they endorse any commercial product or service mentioned or advised on in any of these websites.  

We have established an Editorial Team from within the Scottish Hereditary Cancer Genetics Clinical Pathways Group to oversee development and maintenance of this toolkit. The content of this toolkit was reviewed by the Editorial Team and signed off by the Scottish Cancer Strategy Board.

The Scottish Hereditary Cancer Genetics Clinical Pathways Group will continue to oversee the development and management of the toolkit and request further approval from the Scottish Cancer Strategy Board as required.

The email for the Editorial Team is available in the "Key contacts" section above and can be used to highlight any feedback or complaints.

All content has been approved by the Editorial team to ensure its accuracy and to mitigate any risks to patient safety.